Date: 2014-09-15
Type of information: Nomination
Compound:
Company: Epizyme (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement:
Action mechanism:
Disease:
Details: Epizyme announced the appointments of Peter Ho , M.D., Ph.D., as Chief Development Officer and Michael Shih , J.D. as Vice President, Business Development. Dr. Ho will lead Epizyme\'s clinical development, regulatory and translational medicine functions. His prior experience includes positions at Johnson & Johnson, GSK, DuPont Pharma and Novartis. He has successfully led teams and guided therapeutic candidate development from Phase 1 through Phase 3 activities. Dr. Ho\'s development experience includes imatinib (Gleevec®), nelarabine (Arranon®), lapatinib (Tykerb®), pazopanib (Votrient®), and eltrombopag (Promacta®). Mr. Shih will lead Epizyme\'s partnership strategy and execution. Most recently, he served as senior director of business development at Forest Laboratories , where he was responsible for screening, sourcing and negotiating strategic partnership opportunities across several therapeutic areas, including oncology and oncology supportive care. Prior to joining Forest, Mr. Shih held the position of senior director of business development at Eisai, where his accomplishments included the EZH2 collaboration with Epizyme.
Financial terms:
Latest news:
